پديدآورندگان :
masoud Gandomkar Dept. of Medical Biotechnology, Faculty of Advance Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran , Mohammad Rahmati Dept. of Clinical Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran , Nosratallah Zarghami Dept. of Medical Biotechnology, Faculty of Advance Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran , Hassan Darushnejad Dept. of Medical Biotechnology, Faculty of Advance Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
كليدواژه :
AML , HL 60 , ABT , 737 , NBD peptide , mdr1
چكيده فارسي :
Acute myeloid leukemia (AML) is a hematological malignancy that the cause of death in adults. In this cancer over expression of Bcl-2 and P-glycoprotein are the two cause of resistance. NF-κB, a transcription factor that enhance expression of the panel of gene, include the two mentioned above molecules. NF-κB is a good target for treatment of cancer and overcoming to drug resistance in cancer therapy. ABT-737 is a novel anti Bcl-2 small molecule drug that is has strong potency to chemotherapy as a new drug.
